ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
09. Mai 2022 07:00 ET
|
ObsEva SA
-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
09. Mai 2022 01:00 ET
|
ObsEva SA
-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
10. Dezember 2021 01:00 ET
|
ObsEva SA
-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3...
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
22. November 2021 01:05 ET
|
ObsEva SA
FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA,...
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
20. Mai 2021 01:00 ET
|
ObsEva SA
-PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment- -Results continue...
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants
27. April 2021 01:00 ET
|
ObsEva SA
-Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 - GENEVA, Switzerland and BOSTON, MA – April...
ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
10. Dezember 2020 01:00 ET
|
ObsEva SA
PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT]) Show...
ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids
24. November 2020 01:00 ET
|
ObsEva SA
If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: 100 mg once daily for women with a contraindication to or who...
ObsEva SA hosts live symposium and presents oral communication at the SEUD Online Week November 3 - 6, 2020
02. November 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
06. Juli 2020 01:00 ET
|
ObsEva SA
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2 results demonstrate sustained efficacy and...